Médecine communautaire et éducation à la santé

Abstrait

Promoting Factors and Barriers to Participation in Early Phase Clinical Trials: Patients Perspectives

Patricia Chalela, Lucina Suarez, Edgar Muñoz, Kipling J Gallion, Brad H Pollock, Steven D Weitman, Anand Karnad and Amelie G Ramirez

Background: Inclusion of minorities in clinical research is an essential step to develop novel cancer treatments, improve health care overall, understand potential differences in pharmacogenomics and address minorities’ disproportionate cancer burden. However, Latinos and other minority groups continue to be critically underrepresented, particularly in EPCTs. The objective of the present study was to explore barriers and promoting factors influencing patients’ decisions to enroll or not in early phase clinical trials (EPCTs) and identify areas for intervention to increase minority enrollment into clinical research.
Methods: An interviewer-administered survey was conducted with 100 cancer patients in the predominantly Latino region of South Texas. Exploratory factor analysis was conducted to identify underlying dimensions, and multiple logistic regressions assessed significant factors that promote or deter patients’ enrollment to EPCTs. In addition, a separate subgroup mean analysis assessed differences by enrollment status and race/ethnicity.
Results: For one standard deviation increase in the importance given to the possibility of symptoms improvement, the predicted odds of refusing enrollment were 3.20 times greater (OR=3.20, 95% CI=1.06-9.71, p 0.040). Regarding barriers, among patients who considered fear/uncertainty of the new treatment a deterrent to enrollment, one standard deviation increase in agreement with these barriers was associated with a 3.60 increase (OR=3.60, 95% CI=1.30-9.97, p 0.014) in the odds of not being enrolled in an EPCT. In contrast, non-enrolled patients were less likely (OR=0.14, 95% CI=0.05-0.44, p 0.001) to consider fatalistic beliefs as an important barrier.
Conclusion: This study, one of the first to identify South Texas patients’ barriers to enroll in EPCTs, highlights potential focal areas to increase participation of both minority and non-minority patients in clinical research. Culturally tailored interventions promoting patient-centered care and bilingual, culturally competent study teams could solve language barriers and enhance Latinos’ likelihood of joining clinical trials. These interventions may simultaneously increase opportunities to involve patients and physicians in clinical trials, while ensuring the benefits of participation are equitably distributed to all patients.